▲ +62.08% Upside Potential
This price target is based on 8 analysts offering 12 month price targets for Replimune Group in the last 3 months. The average price target is $56.00, with a high forecast of $67.00 and a low forecast of $48.00. The average price target represents a 62.08% upside from the last price of $34.55.
The current consensus among 8 polled investment analysts is to buy stock in Replimune Group. This Buy consensus rating has held steady for over two years.
Replimune Group, Inc., a biotechnology company, develops oncolytic immune-gene therapies to treat cancer. It uses its proprietary Immulytic platform to design and develop product candidates that are intended to activate the immune system against cancer. The company's lead product candidate is RP1, a selectively replicating version of herpes simplex virus 1, which is in Phase I/II clinical trials for a range of solid tumors; and that is in Phase II clinical trials for patients with cutaneous squamous cell carcinoma. It is also developing RP2, which is in Phase I clinical trials for an anti-CTLA-4 antibody-like protein in order to block the inhibition of the immune response otherwise caused by CTLA-4; and RP3 to express immune-activating proteins that stimulate T cells. Replimune Group, Inc. was founded in 2015 and is headquartered in Woburn, Massachusetts.